Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
Kathleen N. Moore, MD
Ritu Salani, MD
Treatment Decisions That Matter: A Case-Based Discussion in Advanced Ovarian Cancer
Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
Case Consult: Treatment Strategies for FRα-Positive Platinum-Resistant Ovarian Cancer
The CELMoD Shift: Translating Protein Degradation Science Into Practice-Changing Myeloma Care
December 11, 2026 New Orleans, Louisiana
Data Meets Decision: Expert Approaches to Perioperative Immunotherapy in LA HNSCC
Multiple dates available
Beyond Checkpoint Blockade in SCLC: Emerging Antigen Targets and Treatment Strategies Across Disease Stages
Neal Ready, MD, PhD
Ticiana Leal, MD
The Evidence Base: Key Trials and Emerging Data
Christophe Le Tourneau, MD, PhD
Marc Oliva, MD, PhD
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
Perioperative Immunotherapy in LA-HNSCC: From Evidence to Clinical Practice
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
Precision in Practice—Bringing Targeted Therapy to mHSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Javier Cortes, MD, PhD
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
What’s Next for TROP2-Directed ADCs in TNBC?
Tiffany Traina, MD
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.